Best-in-Class Clinical Impact
Why DroobiSmit?
Best-in-Class
Clinical Impact
Intelligence
in the Product
Geographical
Footprint
Business Model
to Support Clients
PHCC, Qatar: Largest Diabetes Management Study in GCC
Published by American Diabetes Association (ADA)
Cohort of 633 patients across 27 Primary Health Care Corporation (PHCC) clinics
Outcome Highlights
Reduction in HbA1c:
0.91% reduction for patients with initial HbA1c ≥ 8
Reduction in Cholesterol:
0.81 mmol/L reduction in total cholesterol for patients with cholesterol levels ≥ 5.18 mmol/L
Reduction in Blood Pressure:
7.84% reduction in systolic blood pressure for patients
with initial BP ≥ 130/80
Reduction in Weight:
0.72% reduction in BMI for patients with initial BMI ≥ 25
India: Large-Scale Diabetes Management Study
Published by American Diabetes Association (ADA)
Cohort of 808 patients across 50 cities in India
Outcome Highlights
Reduction in HbA1c:
1.10% reduction for 808 patients
Increase in Time in Range (TIR):
7.16% increase for patients with initial TIR of 40.3% ± 31%
Reduction in HbA1c (Uncontrolled Diabetes):
2.18% reduction for patients with initial HbA1c ≥ 9
Case Study: Leading Clinic Chain in India
Obesity and Diabetes Management Program
Outcome Highlights
Reduction in HbA1c:
1.40% average reduction
Reduction in BMI:
3.35 average reduction for most compliant users
Reduction in Weight:
3.50kg average reduction
Best-in-Class Clinical Impact
Why DroobiSmit?
Best-in-Class
Clinical Impact
Intelligence
in the Product
Geographical
Footprint
Business Model
to Support Clients
PHCC, Qatar: Largest Diabetes Management Study in GCC
Published by American Diabetes Association (ADA)
Cohort of 633 patients across 27 Primary Health Care Corporation (PHCC) clinics
Outcome Highlights
Reduction in HbA1c:
0.91% reduction for patients with initial HbA1c ≥ 8
Reduction in Cholesterol:
0.81 mmol/L reduction in total cholesterol for patients with cholesterol levels ≥ 5.18 mmol/L
Reduction in Blood Pressure:
7.84% reduction in systolic blood pressure for patients
with initial BP ≥ 130/80
Reduction in Weight:
0.72% reduction in BMI for patients with initial BMI ≥ 25
India: Large-Scale Diabetes Management Study
Published by American Diabetes Association (ADA)
Cohort of 808 patients across 50 cities in India
Outcome Highlights
Reduction in HbA1c:
1.10% reduction for 808 patients
Increase in Time in Range (TIR):
7.16% increase for patients with initial TIR of 40.3% ± 31%
Reduction in HbA1c (Uncontrolled Diabetes):
2.18% reduction for patients with initial HbA1c ≥ 9
Case Study: Leading Clinic Chain in India
Obesity and Diabetes Management Program
Outcome Highlights
Reduction in HbA1c:
1.40% average reduction
Reduction in BMI:
3.35 average reduction for most compliant users
Reduction in Weight:
3.50kg average reduction
Best-in-Class Clinical Impact
Why DroobiSmit?
Best-in-Class
Clinical Impact
Intelligence
in the Product
Geographical
Footprint
Business Model
to Support Clients
PHCC, Qatar: Largest Diabetes Management Study in GCC
Published by American Diabetes Association (ADA)
Cohort of 633 patients across 27 Primary Health Care Corporation (PHCC) clinics
Outcome Highlights
Reduction in HbA1c:
0.91% reduction for patients with initial HbA1c ≥ 8
Reduction in Cholesterol:
0.81 mmol/L reduction in total cholesterol for patients with cholesterol levels ≥ 5.18 mmol/L
Reduction in Blood Pressure:
7.84% reduction in systolic blood pressure for patients
with initial BP ≥ 130/80
Reduction in Weight:
0.72% reduction in BMI for patients with initial BMI ≥ 25
India: Large-Scale Diabetes Management Study
Published by American Diabetes Association (ADA)
Cohort of 808 patients across 50 cities in India
Outcome Highlights
Reduction in HbA1c:
1.10% reduction for 808 patients
Increase in Time in Range (TIR):
7.16% increase for patients with initial TIR of 40.3% ± 31%
Reduction in HbA1c (Uncontrolled Diabetes):
2.18% reduction for patients with initial HbA1c ≥ 9
Case Study: Leading Clinic Chain in India
Obesity and Diabetes Management Program
Outcome Highlights
Reduction in HbA1c:
1.40% average reduction
Reduction in BMI:
3.35 average reduction for most compliant users
Reduction in Weight:
3.50kg average reduction